• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Revolutionary New Test May Detect Cancer Earlier

Posted on: Thursday, 2 November 2006, 09:00 CST

NEW YORK, Nov. 2 /PRNewswire/ -- According to recent studies, the risk of cancer increases as people age. In the United States alone, men have a one in two lifetime risk of developing cancer, while women have a one in three lifetime risk. Unfortunately, experts also agree that cancer could soon replace heart disease as the leading cause of death in the United States.

"It's certainly not a pleasant fact to face, but it's true," says Dr. Ricardo Moro-Vidal. "The rate of some cancers has been increasing for many decades. It's only recently, however, that true methods have been discovered to detect the problem at an early stage."

"Markers" Identify Cancer

Dr. Moro-Vidal is President and CEO of BioCurex (http://biocurex.com/) a cancer research and development company that has developed a method of cancer detection surpassing others in the field. Using their patented RECAF technology, scientists at BioCurex can differentiate cancer cells from healthy cells in ways that previous scientists have been unable to do.

"Cancer markers help distinguish cancer cells from non-cancerous cells," says Dr. Moro-Vidal. "The ideal marker is a molecule that's present in all cancer cells of all tissue types -- none of the present markers can do that; and RECAF is the only one discovered to date that comes very close to that ideal." Cancer markers, as scientists refer to them, are molecules found in human cells that identify certain cellular characteristics. By notating whether markers are present or not, scientists are able to determine whether a cell is normal, benign, or cancerous. Although the best cancer markers to date (AFP, CEA, PSA, and Ca125) have been somewhat effective in identifying cancer, they are limited by their ability to identify cancer only in certain organs. RECAF, on the other hand, works across the board, showing very high sensitivity and specificity in all cancers so far studied, including lung, breast, prostate, ovarian, cervical, colorectal, stomach and others. These types represent the vast majority of all cancers.

A further advantage of RECAF is that it's found in not only the tissue of cancer patients so biopsies can be examined; but also in the bloodstream so that a simple blood test can be used to detect cancer.

"Having the ability to find the marker in the bloodstream is a tremendous advantage over doing a biopsy," states Dr. Moro-Vidal. "It's simple, it's efficient, and it can be applied to some of the most common types of cancer for which there are no other useful markers."

Clinical Testing

At the annual meeting of the International Society for Oncofetal Biology and Medicine, BioCurex presented its results on blood testing for cancer detection. The company's RECAF test detected twice the amount of cancer than PSA, another widely used cancer detection test.

"The medical community definitely has something to take note of," says Dr. Moro-Vidal about RECAF. "I'm lucky and proud to be a part of this significant step in medicine."

Contact: Jacqueline Bodnar JB@SyndicatedNews.us (248) 798-8760

Syndicated News, Inc.

CONTACT: Jacqueline Bodnar, Syndicated News, Inc., +1-248-798-8760,JB@SyndicatedNews.us

Web Site: http://biocurex.com/

Source: PRNewswire

More News in this Category